ConcertAI has acquired CancerLinQ, an oncology-focused real-world information service, from the American Society of Scientific Oncology (ASCO), for an undisclosed quantity. 

Cambridge, Mass.-based ConcertAI is a for-profit firm targeted on oncology real-world information, digital-accelerated medical trial options, and medical synthetic intelligence imaging interpretation. The nonprofit ASCO represents almost 50,000 oncology professionals who take care of folks residing with most cancers.

A narrative in Most cancers Letter famous that ConcertAI, by a predecessor agency known as Precision Well being AI, has been working with ASCO for 5 years, curating and licensing the info in CancerLinQ.

Most cancers Letter creator Paul Goldberg requested if the practices that offered information to ASCO, a nonprofit, would now present the info to a for-profit entity working in a aggressive market.

“I hope so, as a result of I believe that their expertise—the worth they understand from their engagement—goes to grow to be a greater one,” ASCO’s Chief Govt Officer Clifford Hudis, M.D. responded. “I don’t wish to communicate for no matter ConcertAI could select to do with CancerLinQ, however I believe that the standard of the providers that they obtain ought to quickly enhance.”

Along side the acquisition, ASCO will keep a multi-year cooperation settlement with CancerLinQ, which was launched by ASCO in 2013. ConcertAI mentioned the brand new enterprise will improve and increase CancerLinQ’s use of real-world information, analytics, next-generation AI, and different applied sciences to enhance most cancers care and velocity medical analysis.

CancerLinQ represents one of many largest oncology real-world information  and high quality of care expertise providers entities on the planet, bringing collectively medical information from most main EHR programs. With a community of greater than 100 most cancers facilities and oncology practices, 10 EHR system integrations, and information from almost seven million affected person information, CancerLinQ empowers oncology care groups and researchers with expertise and information improvements to enhance care and speed up most cancers analysis.
 
CancerLinQ will stay targeted on high quality and advancing the rules of precision drugs, increasing real-world information for a broader set of analysis functions, and supporting a brand new medical trials initiative evolving from CancerLinQ’s TriaLinQ  ideas. CancerLinQ will work carefully with ASCO to prioritize the wants of oncology practices and help the growth of the apply community.

“We consider this settlement will present the assets to satisfy and amplify CancerLinQ’s affect, whereas permitting ASCO to harness the CancerLinQ platform for high quality enchancment initiatives and CancerLinQ Discovery information for analysis to help our mission,” mentioned ASCO’s Hudis in a press release. “We anticipate CancerLinQ to be an necessary avenue for practices to attain certification beneath ASCO’s just lately launched ASCO Licensed program.”
 
“CancerLinQ could also be some of the necessary oncology networks in existence.  We’re happy and privileged to have the ability to advance the unique high quality enchancment targets and follow-on analysis pursuits of CancerLinQ in collaboration with ASCO, with urgency and alacrity,” mentioned Jeff Elton, Ph.D., CEO of ConcertAI, in a press release. “We’re committing greater than $250 million to the standard options, information options, and novel medical trial options over the approaching few years to attain the very best high quality care, speed up wanted new biomedical improvements, and guarantee the very best outcomes for sufferers.” 
 
ConcertAI will collaborate with ASCO to considerably improve the worth of CancerLinQ for oncology practices and their sufferers by:
• Bolstering SmartLinQ to incorporate new information sources alongside the strong medical information at the moment accessible
• Making medical trials participation extra accessible and fewer burdensome by ConcertAI’s Digital Entry to Scientific Trial (DACT) platform
• Growing extra strong medical determination help inside SmartLinQ
• Supporting automated EHR integration, bringing SmartLinQ seamlessly into practices’ workflows
 
“The scope and scale of what CancerLinQ and ConcertAI can accomplish collectively is unprecedented,” mentioned Eric P. Winer, M.D., chair of the board of ASCO, in a press release. “We’ve efficiently constructed a real-world information platform that delivers actionable insights to the most cancers group – and now CancerLinQ is poised to maintain and enhance its affect for oncology practices and sufferers for the long run.”